Deciphering CD137 (4‐1BB) signaling in T‐cell costimulation for translation into successful cancer immunotherapy

No abstract is available for this paper.

• Publication year

  2016

• Venue

  European Journal of Immunology

• Publication date

  2016-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/eji.201445388PMID 26773716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting CD137 enhances the efficacy of cetuximab.

  2019cited by this paper
• Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.

  2016cited by this paper
• CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity

  2016cited by this paper
• Combination cancer immunotherapy and new immunomodulatory targets

  2015cited by this paper
• Evolving synergistic combinations of targeted immunotherapies to combat cancer

  2015cited by this paper
• Adoptive cell transfer as personalized immunotherapy for human cancer

  2015cited by this paper
• ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment

  2015cited by this paper
• Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.

  2015cited by this paper
• 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors

  2015cited by this paper
• A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL.

  2015cited by this paper
• Phenotypic switch of CD8+ T cells reactivated under hypoxia toward IL‐10 secreting, poorly proliferative effector cells

  2015cited by this paper
• c‐IAP ubiquitin protein ligase activity is required for 4‐1BB signaling and CD8+ memory T‐cell survival

  2015cited by this paper
• Inhibitory receptors as targets for cancer immunotherapy

  2015cited by this paper
• 4-1BB Ligand Signaling to T Cells Limits T Cell Activation

  2015cited by this paper
• Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

  2015cited by this paper
• Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.

  2015cited by this paper
• Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine

  2015cited by this paper
• Hematopoietic stem cell quiescence and function are controlled by the CYLD–TRAF2–p38MAPK pathway

  2015cited by this paper
• Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies

  2014cited by this paper
• Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies

  2014cited by this paper
• SA-4-1BBL and monophosphoryl lipid A constitute an efficacious combination adjuvant for cancer vaccines.

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects

  2014cited by this paper
• Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy

  2014cited by this paper
• PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

  2014cited by this paper
• Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model

  2014cited by this paper
• Targeting CD137 enhances the efficacy of cetuximab.

  2014cited by this paper
• Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

  2014cited by this paper
• T Cell Costimulation with Anti-CD137 Monoclonal Antibodies Is Mediated by K63–Polyubiquitin-Dependent Signals from Endosomes

  2013cited by this paper
• Regulation of NF-κB by ubiquitination.

  2013cited by this paper
• Leukocyte‐specific protein 1 links TNF receptor‐associated factor 1 to survival signaling downstream of 4‐1BB in T cells

  2013cited by this paper
• Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model

  2013cited by this paper
• Co-Stimulation through 4-1BB/CD137 Improves the Expansion and Function of CD8+ Melanoma Tumor-Infiltrating Lymphocytes for Adoptive T-Cell Therapy

  2013cited by this paper
• Agonistic CD40 Antibodies and Cancer Therapy

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo

  2013cited by this paper
• Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation

  2013cited by this paper
• Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice.

  2013cited by this paper
• Inducible Tumor Necrosis Factor (TNF) Receptor-associated Factor-1 Expression Couples the Canonical to the Non-canonical NF-κB Pathway in TNF Stimulation*

  2013cited by this paper
• Pharmacokinetics and Biodistribution of a Human Monoclonal Antibody to Oxidized LDL in Cynomolgus Monkey Using PET Imaging

  2012cited by this paper
• Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12.

  2012cited by this paper
• Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.

  2012cited by this paper
• Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.

  2012cited by this paper
• Ubiquitination in signaling to and activation of IKK

  2012cited by this paper
• Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies.

  2012cited by this paper
• Opposing Roles for TRAF1 in the Alternative versus Classical NF-κB Pathway in T Cells*

  2012cited by this paper
• CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.

  2012cited by this paper
• Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.

  2011cited by this paper
• Abstract 765: Costimulatory SA-4-1BBL and monophosphoryl lipid A as novel adjuvant system for the development of cancer vaccines with robust therapeutic efficacy

  2011cited by this paper
• The role of ubiquitylation in immune defence and pathogen evasion

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.

  2011cited by this paper
• Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

  2011cited by this paper
• Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

  2011cited by this paper
• Intratumoral injection of interferon‐α and systemic delivery of agonist anti‐CD137 monoclonal antibodies synergize for immunotherapy

  2011cited by this paper
• In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).

  2011cited by this paper
• Novel Phosphorylation-dependent Ubiquitination of Tristetraprolin by Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase Kinase 1 (MEKK1) and Tumor Necrosis Factor Receptor-associated Factor 2 (TRAF2)*

  2011cited by this paper
• CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.

  2011cited by this paper
• 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines.

  2010cited by this paper
• Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

  2010cited by this paper
• Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

  2010cited by this paper
• Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.

  2010cited by this paper
• Asymmetric recruitment of cIAPs by TRAF2.

  2010cited by this paper
• Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains

  2009cited by this paper
• Ubiquitylation in innate and adaptive immunity

  2009cited by this paper
• In vivo depletion of DC impairs the anti‐tumor effect of agonistic anti‐CD137 mAb

  2009cited by this paper
• Structural basis for the lack of E2 interaction in the RING domain of TRAF2.

  2009cited by this paper
• Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy

  2009cited by this paper
• Lysine 63 Polyubiquitination in Immunotherapy and in Cancer-promoting Inflammation

  2009cited by this paper
• The Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor Superfamily*

  2009cited by this paper
• Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity.

  2008cited by this paper
• Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

  2008cited by this paper
• Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities

  2008cited by this paper
• Immune regulation and control of regulatory T cells by OX40 and 4-1BB.

  2008cited by this paper
• Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.

  2008cited by this paper
• ERK-Dependent Bim Modulation Downstream of the 4-1BB-TRAF1 Signaling Axis Is a Critical Mediator of CD8 T Cell Survival In Vivo1

  2008cited by this paper
• T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection

  2007cited by this paper
• Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy.

  2007cited by this paper
• Study of Relieving Graft-versus-Host Disease by Blocking CD137-CD137 Ligand Costimulatory Pathway in Vitro

  2007cited by this paper
• Genes that distinguish physiological and pathological angiogenesis.

  2007cited by this paper
• Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities.

  2007cited by this paper
• Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.

  2007cited by this paper
• Eradication of established tumors in mice by a combination antibody-based therapy

  2006cited by this paper
• Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.

  2006cited by this paper
• Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.

  2006cited by this paper
• The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma

  2005cited by this paper
• Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus.

  2005cited by this paper
• Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation.

  2005cited by this paper
• Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti‐OX40 and anti‐4‐1BB monoclonal antibodies induces T cell–mediated protective immunity in Her‐2/neu transgenic mice

  2005cited by this paper
• Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens

  2004cited by this paper
• 4-1BB-mediated immunotherapy of rheumatoid arthritis

  2004cited by this paper
• Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines

  2004cited by this paper
• CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.

  2003cited by this paper
• Tumor Necrosis Factor (TNF)-induced Germinal Center Kinase-related (GCKR) and Stress-activated Protein Kinase (SAPK) Activation Depends upon the E2/E3 Complex Ubc13-Uev1A/TNF Receptor-associated Factor 2 (TRAF2)*

  2003cited by this paper
• Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?

  2003cited by this paper
• Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model.

  2003cited by this paper
• TRAF1: Lord Without A RING

  2002cited by this paper
• 4-1BB Promotes the Survival of CD8+ T Lymphocytes by Increasing Expression of Bcl-xL and Bfl-11

  2002cited by this paper
• 4-1BB-Specific Monoclonal Antibody Promotes the Generation of Tumor-Specific Immune Responses by Direct Activation of CD8 T Cells in a CD40-Dependent Manner

  2002cited by this paper
• Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB

  2002cited by this paper

• CD137 might be a pivotal regulator of Th1/Th17-driven autoimmunity and B-cell hyperactivity in hyperthyroidism.

  2025cites this paper
• Hole in one: CD137-ADC eliminates GVHD.

  2025cites this paper
• Recent Advancements in Immunotherapy for the Treatment of Metastatic Breast Cancer.

  2025cites this paper
• Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases

  2025cites this paper
• A mechanistic quantitative systems pharmacology model platform for translational efficacy evaluation and checkpoint combination design of bispecific immuno-modulatory antibodies

  2025cites this paper
• Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors

  2025cites this paper
• MD Simulation Reveals a Trimerization-Enhanced Interaction of CD137L with CD137

  2025cites this paper
• Regulatory T cell and endothelial cell crosstalk

  2025cites this paper
• CAR T cells and metabolic programming: A review

  2025cites this paper
• Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin’s lymphoma

  2024cites this paper
• CAR‑T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

  2024cites this paper
• Radiolabelling and preclinical characterisation of [89Zr]Zr-Df-ATG-101 bispecific to PD-L1/4–1BB

  2024cites this paper
• CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool

  2024cites this paper
• Therapeutic prospects of nectin-4 in cancer: applications and value

  2024cites this paper
• Transcriptional reprogramming via signaling domains of CD2, CD28, and 4-1BB

  2024cites this paper
• Fueling CARs: metabolic strategies to enhance CAR T-cell therapy

  2024cites this paper
• A platform trial of neoadjuvant and adjuvant antitumor vaccination alone or in combination with PD-1 antagonist and CD137 agonist antibodies in patients with resectable pancreatic adenocarcinoma

  2023cites this paper
• XCR1+ DCs are critical for T cell-mediated immunotherapy of chronic viral infections.

  2023cites this paper
• The differential effect of the immune system in breast cancer

  2023cites this paper
• Nectin-4 has emerged as a compelling target for breast cancer.

  2023cites this paper
• 4-1BB Targeting Immunotherapy: Mechanism, Antibodies, and Chimeric Antigen Receptor T

  2023cites this paper
• Fundamental Characterization of Antibody Fusion-Single-Chain TNF Recombinant Proteins Directed against Costimulatory TNF Receptors Expressed by T-Lymphocytes

  2023cites this paper
• Regulation and Immunotherapeutic Targeting of the Epigenome in Exhausted CD8 T Cell Responses.

  2023cites this paper
• Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc)

  2022cites this paper
• Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

  2022cites this paper
• Metabolic Regulation of T cell Activity: Implications for Metabolic-Based T-cell Therapies for Cancer

  2022cites this paper
• CD3‐T‐cell‐engager (TCE) therapies to overcome solid tumors: Beyond BiTEs

  2022cites this paper
• Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy

  2022cites this paper
• First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors

  2022cites this paper
• Identification of a binding site on soluble RANKL that can be targeted to inhibit soluble RANK-RANKL interactions and treat osteoporosis

  2022cites this paper
• Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma

  2022cites this paper
• Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer

  2022cites this paper
• Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology

  2022cites this paper
• Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB

  2022cites this paper
• Protein scaffolds: antibody alternatives for cancer diagnosis and therapy

  2022cites this paper
• Immune Cell Metabolic Fitness for Life

  2022cites this paper
• 4-1BB/4-1BBL signaling pathway in patients with influenza A (H1N1) virus-associated pneumonia

  2022cites this paper
• Sintilimab-induced autoimmune diabetes: A case report and review of the literature

  2022cites this paper
• Metabolic Implications of Immune Checkpoint Proteins in Cancer

  2022cites this paper
• CD137L-macrophage induce lymphatic endothelial cells autophagy to promote lymphangiogenesis in renal fibrosis

  2022cites this paper
• Glofitamab CD20-TCB bispecific antibody

  2021cites this paper
• TNFSF9 promotes metastasis of pancreatic cancer by regulating M2 polarization of macrophages through Src/FAK/p-Akt/IL-1β signaling.

  2021cites this paper
• The role of TNFRSF7 and TNFRSF9 receptors in the development of systemic inflammation in patients with viral pneumonia

  2021cites this paper
• BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™ (Bicycle TICA™) induces tumor localized CD137 agonism

  2021cites this paper
• Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer

  2021cites this paper
• Contributions of Costimulatory Molecule CD137 in Endothelial Cells

  2021cites this paper
• An oncolytic vaccinia virus armed with anti-human-PD-1 antibody and anti-human-4-1BB antibody double genes for cancer-targeted therapy.

  2021cites this paper
• Activation of 4-1BB signaling in bone marrow stromal cells triggers bone loss via the p-38 MAPK-DKK1 axis in aged mice

  2021cites this paper
• Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory

  2021cites this paper
• A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

  2021cites this paper
• CD137+ T-Cells: Protagonists of the Immunotherapy Revolution

  2021cites this paper
• A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy

  2020cites this paper
• Nuclear-localized costimulatory molecule 4-1BBL promotes colon cancer cell proliferation and migration by regulating nuclear Gsk3β, and is linked to the poor outcomes associated with colon cancer

  2020cites this paper
• The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention

  2020cites this paper
• 小细胞肺癌免疫治疗及预后相关标志物的研究进展

  2020cites this paper
• First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

  2020cites this paper
• Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours

  2020cites this paper
• 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling

  2020cites this paper
• Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy

  2020cites this paper
• CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement

  2020cites this paper
• The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells

  2020cites this paper
• Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation

  2020cites this paper
• New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis

  2020cites this paper
• Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer

  2020cites this paper
• Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma

  2020cites this paper
• Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)

  2020cites this paper
• CD137 agonist induces gastric cancer cell apoptosis by enhancing the functions of CD8+ T cells via NF-κB signaling

  2020cites this paper
• Expamers: a new technology to control T cell activation

  2020cites this paper
• Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment

  2020cites this paper
• Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history

  2020cites this paper
• A metabolic switch to memory CAR T cells: Implications for cancer treatment.

  2020cites this paper
• Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy

  2020cites this paper
• Potentiating Tumor Immunity Using Aptamer-Targeted RNAi to Render CD8+ T Cells Resistant to TGFÎ2 Inhibition

  2020cites this paper
• Allergen‐specific immunotherapy enhances CD8+ CD25+ CD137+ regulatory T cells and decreases nasal nitric oxide

  2019cites this paper
• Destroy, what destroys you

  2019cites this paper
• Increased Peripheral CD137 Expression in a Mouse Model of Permanent Focal Cerebral Ischemia

  2019cites this paper
• Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment

  2019cites this paper
• TNFRSF9 (TNF receptor superfamily member 9)

  2019cites this paper
• Bifunctional Fusion Proteins Derived from Tumstatin and 4-1BBL for Targeted Cancer Therapy.

  2019cites this paper
• The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma

  2019cites this paper
• Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC.

  2019influential citation
• Electrostatic interactions: From immune receptor assembly to signaling

  2019cites this paper
• Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

  2019cites this paper
• Carcinoembryonic Antigen (CEA)-Specific 4-1BB-Costimulation Induced by CEA-Targeted 4-1BB-Agonistic Trimerbodies

  2019cites this paper
• OMIP‐060: 30‐Parameter Flow Cytometry Panel to Assess T Cell Effector Functions and Regulatory T Cells

  2019cites this paper
• A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors

  2019cites this paper
• The promise of CD4+FoxP3+ regulatory T-cell manipulation in vivo: applications for allogeneic hematopoietic stem cell transplantation

  2019cites this paper
• Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343

  2019cites this paper
• The TNF-TNFR Family of Co-signal Molecules.

  2019cites this paper
• Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier

  2018influential citation
• Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer

  2018cites this paper
• Crystal structure of m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon receptor binding

  2018cites this paper
• Immunomodulation with Radiation

  2018cites this paper
• Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer

  2018cites this paper
• Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding

  2018cites this paper
• CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs

  2018cites this paper
• Activation of CD137 Signaling Enhances Vascular Calcification through c-Jun N-Terminal Kinase-Dependent Disruption of Autophagic Flux

  2018cites this paper
• T Lymphocyte-Based Cancer Immunotherapeutics.

  2018cites this paper
• Understanding How the Costimulatory Molecule OX40 Engagement on T Cells Can Boost Immune Responses for Vaccine Applications and Immunotherapy.

  2018cites this paper
• Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function

  2018cites this paper